Encorafenib

(Braftovi®)

Encorafenib

Drug updated on 11/16/2023

Dosage FormCapsule (oral; 75 mg)
Drug ClassKinase inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated, in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
  • Indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.

Product Monograph / Prescribing Information

Document TitleYearSource
Braftovi (encorafenib) Prescribing Information.2023Array BioPharma Inc., Boulder, CO

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: results from a systematic literature review and a network meta-analysis.2022Cancer Treatment Reviews
Acceptability of Drugs in the Treatment of Unresectable/Metastatic BRAF V600-Mutant Melanoma: A Systematic Review and Network Meta-Analysis. 2022Frontiers in Oncology
Systematic review of randomised clinical trials and observational studies for patients with RAS wild-type or BRAFV600E-mutant metastatic and/or unresectable colorectal cancer. 2022Critical Reviews in Hematology/Oncology
Clinical and Pharmacoeconomic combined report: encorafenib in combination with binimetinib (Braftovi and Mektovi).2021CADTH
Clinical and Pharmacoeconomic combined report: encorafenib (Braftovi).2021CADTH
Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer. 2021NICE
Systematic review of BRAF/MEK inhibitors-induced Severe Cutaneous Adverse Reactions (SCARs). 2021Journal of the European academy of Dermatology & Venereology
Comparative efficacy of dabrafenib + trametinib versus treatment options for metastatic melanoma in first-line settings. 2021Journal of comparative effectiveness research
Assessment report: Braftovi.2020EMA
A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma. 2019European Journal of Cancer
Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma.2019NICE
Efficacy and adverse events in metastatic melanoma patients treated with combination BRAF plus MEK inhibitors versus BRAF Inhibitors: a systematic review.2019Cancers
Cardiovascular Adverse Events Associated With BRAF and MEK Inhibitors: A Systematic Review and Meta-analysis. 2019JAMA Network Open

Clinical Practice Guidelines